Navigation Links
/C O R R E C T I O N -- Rosetta Genomics Ltd/
Date:5/21/2008

non-small cell lung cancer (NSCLC) and is the first of three tests the company expects will be submitted for regulatory approval by CLIA certified labs in 2008.

In addition, the company recently announced an agreement with the University of California, Irvine School of Medicine to develop diagnostic tests based on Rosetta's proprietary microRNA technology.

On the scientific front, in a paper published in the April issue of Nature Biotechnology, Rosetta Genomics and collaborators demonstrated the significant potential of microRNAs to be used as biomarkers for diagnosing the primary tumor site in patients with cancer of unknown primary (CUP). The company expects a CUP test based on its microRNA technology to be submitted for regulatory approval by a CLIA certified lab by the end of 2008.

Financial Overview

Operating loss for the first quarter of 2008 was $3.7 million (including a non-cash expense of $191,000 related to stock based compensation), compared with an operating loss of $2.2 million (including a non-cash expense of $205,000 related to stock based compensation) for the corresponding quarter of 2007. Net loss for the first quarter of 2008 was $3.9 million, or $0.33 per ordinary share, compared with a net loss of $2 million, or $0.23 per ordinary share, for the corresponding quarter of 2007.

Research and development expenses of $2.4 million for the first quarter of 2008, compared to $1.2 million for the first quarter of 2007, remain the Company's largest expense and accounted for 64% of its operating losses.

As of March 31, 2008 we had $18.6 million in cash, cash equivalents, short and long term bank deposits and marketable securities. Our outlook of total cash usage for operating activities for the next nine month of 2008 is approximately $10 million.

As previously announced, the Company continues to receive interest payments from its auction rate securities, which all but two are rated AAA. However, due to the
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
4. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
5. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
6. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
7. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
8. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
9. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
10. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
11. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... 16, 2013 Scientists at the Center for ... , and the California -based biopharmaceutical ... novel therapy for reversing memory decline in mice with ... significant cognitive improvement in advanced stage AD mice. The ... reversing cognitive decline for advanced stage AD mice, and ...
(Date:5/16/2013)... 16, 2013 Reportlinker.com announces ... is available in its catalogue: ... Analysis: Therapeutic Proteins – Biosimilars, Biobetters ...   Product ... The new Competitive Intelligence Report Therapeutic ...
(Date:5/16/2013)... ON (PRWEB) May 16, 2013 DNA Genotek, ... announced ‘Spit for Africa’, a sponsorship program in conjunction with ... is designed to improve access and reduce the cost of ... projects such as the Human Heredity and Health in Africa ... the AfSHG. , The aim of the AfSHG ...
(Date:5/16/2013)... May 16, 2013 Leading UK ... Success for Companion Diagnostic–Drug Pairings in Oncology, a ... biopharmaceutical manufacturers should understand when developing new drug-test ... particularly in oncology, with two recently approved drug–test ... BRAF-mutation positive melanoma. Payors are willing to consider ...
Breaking Biology Technology:Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 3Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 2Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 3Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 4Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 5Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 6Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 7Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 8DNA Genotek Inc. Announces Spit for Africa Program 2DNA Genotek Inc. Announces Spit for Africa Program 3Market Access Expert Firm, PRMA Consulting, Launches Companion Diagnostics Handbook 2
... COLUMBUS, Ohio -- Engineers at Ohio State University are ... from the same material found in pencils. , Experts ... found in graphite pencils -- holds the key to ... effects that could enable new kinds of electronics. , ...
... recent analysis of the elastic nonwovens market, Frost & Sullivan ... & Sullivan Technology Leadership of the Year Award for its ... block copolymers (SBCs). Already established as an innovator in this ... SBCs, the MD6705, G1643, and MD6717 grades are in a ...
... Pharmaceuticals, Inc. (NYSE: WPI ), a leading ... District Court for the District of Delaware has ruled ... tablets) does not infringe United States Patent No. 6,919,373 ... invalid. The opinion, dated March 30, 2009, was ...
Cached Biology Technology:Researchers find better way to manufacture fast computer chips 2Researchers find better way to manufacture fast computer chips 3Frost & Sullivan Recognizes Kraton Polymers for Developing a New Generation of Polymer Grades Suitable for High-Speed Processing in Nonwoven Manufacture 2Frost & Sullivan Recognizes Kraton Polymers for Developing a New Generation of Polymer Grades Suitable for High-Speed Processing in Nonwoven Manufacture 3Frost & Sullivan Recognizes Kraton Polymers for Developing a New Generation of Polymer Grades Suitable for High-Speed Processing in Nonwoven Manufacture 4Frost & Sullivan Recognizes Kraton Polymers for Developing a New Generation of Polymer Grades Suitable for High-Speed Processing in Nonwoven Manufacture 5Delaware Court Rules That Watson Does Not Infringe Patent Related to Generic Version of Concerta(R) and Declares Patent Invalid 2
(Date:5/17/2013)... Efficient and Sustainable Global Logistics Operations) is aiming to ... efficiency of intermodal loading systems and the boosting of ... European organisations with experience in the logistics sector and ... 17,000,000 and a duration of three and a half ... the semantic components and ontologies shared by the users, ...
(Date:5/17/2013)... An international team of scientists ... and cell movement inside a living frog embryo in ... new method to advance biological research and the search ... University and the Karlsruher Institut fr Technologie in Germany, ... U.S. Department of Energy,s Argonne National Laboratory, released the ...
(Date:5/16/2013)... MARC (Maximizing Access to Research Careers) Program has ... for Developmental Biology (SDB) 72nd Annual Meeting in ... are meant to promote the entry of students, ... mainstream of the basic science community and to ... SDB 2013 Annual Meeting. , Awards are given ...
Breaking Biology News(10 mins):New logistics services that will cut energy consumption and CO2 emissions 2New X-ray method shows how frog embryos could help thwart disease 2
... A recently discovered signaling system in the brain has ... an Oregon Health & Science University study found. , ... therapies aiming to reverse meth’s adverse health effects as ... , Working in the recently opened Program in ...
... University of Missouri-Columbia, recently found fossil evidence in seven ... that showed people were eating domesticated chili peppers as ... one of the oldest domesticated food sources in the ... 15 edition of the journal Science. , "Before our ...
... they both infect the liver, the hepatitis A and ... The two are far apart genetically, are transmitted differently, ... the consumption of fecal particles from an infected person ... C is generally transmitted only by direct contact with ...
Cached Biology News:OHSU lab finds meth receptor that could lead to therapy 2OHSU lab finds meth receptor that could lead to therapy 3Researchers find 6,000-year-old fossil evidence 2Researchers find hepatitis A and hepatitis C attack same protein to block immune defenses 2
... Highly nutritious peptone, ... the production of bacterial ... cultivation of bacteria with ... Corynbacterium, Haemophilus, Neisseria, Pasteurella, ...
... in Minimum Essential Medium (Eagle) with 2 mM ... growth. In order to keep the antigens ... acetone-methanol. The cells are arrayed on a ... wells surface specifically treated to enhance cellular attachment ...
... cells were cultured in Ham's F12K medium with ... phase of growth. In order to keep the ... in acetone-methanol. The cells are arrayed on a ... wells surface specifically treated to enhance cellular attachment ...
... cultured in Minimum Essential Medium (Eagle) with 2 ... of growth. In order to keep the ... in acetone-methanol. The cells are arrayed on ... each wells surface specifically treated to enhance cellular ...
Biology Products: